LRMN and Miltenyi Biotec meeting agenda

The March 2015 event will focus on CAR-T therapy

The LRMN’s first meeting of 2015 will discuss cancer immunotherapy using T cells, with presentations by experts on the topic from the University of Pennsylvania, which had joined forces with Novartis, and Juno Therapeutics.

This meeting is supported by Miltenyi Biotec, and is free of charge to attend. It will take place on Tuesday 31st March at UCL, London – see below and the LRMN’s event page for more details.

Agenda

18.00: Registration over tea and coffee in the Gustave Tuck Lecture Theatre (Wilkins Building, UCL)

18.30: Welcome – Dr. Emily Culme-Seymour, LRMN (London, UK) and Jason Jones, Miltenyi Biotec (UK)

18.35: Engineering Targeted Immunity from Patient’s Own Cells to Treat Untreatable Cancers – Professor Bruce Levine, Abramson Cancer Centre of the University of Pennsylvania (Philadelphia, PA, US)

19.15: Q & A

19.20: Juno’s Approach to Cellular Immunotherapy – Hans Bishop, CEO & President, Juno Therapeutics (Seattle, WA, USA)

20.00: Q & A

20.05: Closing remarks – Prof. Chris Mason, Advanced Centre for Biochemical Engineering, UCL (London, UK) and Jason Jones, Miltenyi Biotec (UK)

20.10—22.00: LRMN Reception – Network whilst enjoying a glass of wine or two in the Haldane Room (Wilkins Building, UCL)

Attendance

Are you attending this meeting? Let us know in the comments below!